Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

This study has been completed.
Sponsor:
Information provided by:
Amgen
ClinicalTrials.gov Identifier:
NCT00044902
First received: September 6, 2002
Last updated: December 20, 2007
Last verified: December 2007

September 6, 2002
December 20, 2007
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00044902 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Not Provided

Epratuzumab is currently being studied in combination with rituximab, for the treatment of patients with low-grade NHL who failed previous chemotherapy and have never received rituximab or who received rituximab as a single agent or in combination with chemotherapy as their last treatment and who demonstrated a partial response or complete response for at least 12 months.

Not Provided
Interventional
Phase 2
Primary Purpose: Treatment
Non-Hodgkin's Lymphoma
Drug: epratuzumab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided
  • Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL * Received and failed at least 1 prior regimen of chemotherapy * Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at least 12 months.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00044902
20010138
Not Provided
Global Development Leader, Amgen Inc.
Amgen
Not Provided
Study Director: MD Amgen
Amgen
December 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP